-+ 0.00%
-+ 0.00%
-+ 0.00%

RBC Capital Maintains Outperform on Revolution Medicines, Raises Price Target to $260

Benzinga·10/14/2026 13:43:01
Diffusion vocale
RBC Capital analyst Leonid Timashev maintains Revolution Medicines (NASDAQ:RVMD) with a Outperform and raises the price target from $259 to $260.